Apellis Pharmaceuticals, Inc. (APLS)

Apellis Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May 12, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Cap	5,253	3,181	3,973	7,157	5,728	4,611
Market Cap Growth	117.85%	-19.93%	-44.49%	24.94%	24.23%	5.88%
Enterprise Value	5,322	2,726	3,665	6,910	5,283	4,116
Last Close Price	41.03	25.12	31.91	59.86	51.71	47.28
PE Ratio	39.98	125.60	-	-	-	-
PS Ratio	4.75	3.17	5.08	18.05	75.95	69.27
PB Ratio	12.65	8.59	17.38	36.79	33.72	23.21
P/TBV Ratio	12.81	8.81	17.30	36.52	32.30	20.09
P/FCF Ratio	140.20	70.66	-	-	-	-
P/OCF Ratio	139.07	70.17	-	-	-	-
EV/Sales Ratio	4.82	2.72	4.69	17.42	70.05	61.84
EV/EBITDA Ratio	31.94	47.84	-	-	-	-
EV/EBIT Ratio	32.21	49.19	-	-	-	-
EV/FCF Ratio	142.06	60.57	-	-	-	-
Debt / Equity Ratio	0.03	0.03	0.45	0.54	0.63	1.04
Debt / EBITDA Ratio	0.12	0.33	-	-	-	-
Debt / FCF Ratio	0.53	0.42	-	-	-	-
Net Debt / Equity Ratio	-0.93	-1.21	-1.32	-1.24	-2.58	-2.47
Net Debt / EBITDA Ratio	-2.31	-7.85	1.85	0.47	0.74	0.92
Net Debt / FCF Ratio	-10.29	-9.93	3.41	0.40	0.85	0.87
Asset Turnover	1.02	1.02	0.93	0.51	0.09	0.07
Inventory Turnover	0.79	0.91	1.03	0.50	0.11	0.02
Quick Ratio	2.98	2.57	3.65	2.25	3.34	5.39
Current Ratio	3.63	3.14	4.25	3.10	4.29	6.25
Return on Equity (ROE)	68.94%	7.48%	-93.55%	-290.14%	-353.93%	-370.20%
Return on Assets (ROA)	15.10%	5.25%	-19.83%	-67.04%	-72.50%	-58.24%
Return on Invested Capital (ROIC)	37.00%	15.11%	-58.51%	-298.26%	-868.93%	-4551.49%
Return on Capital Employed (ROCE)	21.31%	7.64%	-26.60%	-91.22%	-88.58%	-67.79%
Earnings Yield	2.54%	0.80%	-	-	-	-
FCF Yield	0.71%	1.42%	-	-	-	-
Buyback Yield / Dilution	-5.48%	-4.80%	-4.40%	-11.84%	-25.70%	-12.32%
Total Shareholder Return	-5.48%	-4.80%	-4.40%	-11.84%	-25.70%	-12.32%

Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q